Covid-19 roundup: Gilead touts preclinical promise for oral remdesivir; Roche prepares for virus to become endemic

With remdesivir still standing as the only antiviral approved to treat Covid-19, Gilead has been exploring new ways to expand its use. Now its researchers, in collaboration with a team from the University of Carolina in Chapel Hill, have come up with preclinical results backing up an oral candidate.


Click to view original post